FARMAKOLOGIK TERAPIYANING BOLALARDA TUG‘MA YURAK NUQSONLARI BILAN BOG‘LIQ GEMODINAMIK O‘ZGARISHLARGA TA’SIRI
Keywords:
Kalit so‘zlar: tug‘ma yurak nuqsonlari, gemodinamika, shunt, o‘pka qon oqimi, PGE₁, diuretiklar, o‘pka gipertenziyasi, milrinon.Abstract
Maqolada bolalardagi tug‘ma yurak nuqsonlarida (TYuN) farmakologik terapiyaning shunt oqimi, o‘pka va tizimli tomir qarshiligi, qorincha yuklamasi hamda yurak chiqish hajmiga ta’siri bo‘yicha dalillar sharh qilindi. 30 ta xalqaro qo‘llanma, ilmiy bayonot, klinik tadqiqot va tizimli sharh tahlil etildi. Duktusga bog‘liq qon aylanishida prostaglandin E₁ (PGE₁) hayotiy muhim ko‘prik davosi; chapdan o‘ngga shunt va dimlanishda diuretiklar simptomni yengillashtirishi mumkin, ammo nuqsonni tuzatmaydi. Chala tug‘ilgan chaqaloqlarda gemodinamik ahamiyatli arterial yo‘lni dori bilan yopish foydasi va vaqtini individual baholash lozim; erta rutin davolashni dalillar qo‘llab-quvvatlamaydi. O‘pka arterial gipertenziyasida vazodilatatorlarni tashxis, o‘pka tomir qarshiligi, shunt yo‘nalishi va operabellik mutaxassis markazida baholangandan keyin tanlash kerak. Operatsiyadan keyingi past yurak chiqishida inotrop va inodilatatorlar qo‘llanishi mumkin, biroq samarasi tadqiqotlarda bir xil emas. TYuNda dori davosi, asosan, gemodinamikani barqarorlashtirish, simptomlarni nazorat qilish va korreksiyagacha ko‘prik vazifasini bajaradi; anatomik tuzatishning o‘rnini bosmaydi.
References
1.Amdani S, Conway J, George K, et al. Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circulation. 2024;150:e33–e50. doi:10.1161/CIR.0000000000001245.
2.Irving C, Azeka E, Adorisio R, et al. The International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014). J Heart Lung Transplant. 2025;44(10):e21–e71. doi:10.1016/j.healun.2025.06.003.
3.Kirk R, Dipchand AI, Rosenthal DN, et al. ISHLT guidelines for the management of pediatric heart failure: executive summary. J Heart Lung Transplant. 2014;33(9):888–909. doi:10.1016/j.healun.2014.06.002.
4.Hsu DT, Pearson GD. Heart failure in children: part I: history, etiology, and pathophysiology. Circ Heart Fail. 2009;2(1):63–70. doi:10.1161/CIRCHEARTFAILURE.108.820217.
5.Dipchand AI, Lorts A, VanderPluym C, et al. Management of Pediatric Heart Failure. Korean Circ J. 2024;54(12):794–810. doi:10.4070/kcj.2024.0320.
6.Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021;11(1):323–335. doi:10.21037/cdt-20-358.
7.Ambalavanan N, Aucott SW, Salavitabar A, et al. Patent Ductus Arteriosus in Preterm Infants. Pediatrics. 2025;155(5):e2025071425. doi:10.1542/peds.2025-071425.
8.Mitra S, de Boode WP, Weisz DE, Shah PS. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2023;4:CD013588. doi:10.1002/14651858.CD013588.pub2.
9.Akkinapally S, Hundalani SG, Kulkarni M, et al. Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions. Cochrane Database Syst Rev. 2018;2(2):CD011417. doi:10.1002/14651858.CD011417.pub2.
10.Ohlsson A, Walia R, Shah SS. Use of prostaglandins in duct-dependent congenital heart conditions. Arch Dis Child Educ Pract Ed. 2018;103(3):137–140. doi:10.1136/archdischild-2017-313654.
11.American College of Cardiology. Outpatient Management of Isolated Left-to-Right Shunt Lesions in Pediatric Patients: 2026 ACC Concise Clinical Guidance. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2025.11.020.
12.Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation. 2006;114(17):1873–1882. doi:10.1161/CIRCULATIONAHA.105.592063.
13.Hsu DT, Zak V, Mahony L, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation. 2010;122(4):333–340. doi:10.1161/CIRCULATIONAHA.109.927988.
14.Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation. 1997;96(5):1507–1512. doi:10.1161/01.CIR.96.5.1507.
15.Harteveld LM, Blom NA, Terol Espinosa de Los Monteros C, et al. 3-Month Enalapril Treatment in Pediatric Fontan Patients With Moderate to Good Systolic Ventricular Function. Am J Cardiol. 2022;163:98–103. doi:10.1016/j.amjcard.2021.10.013.
16.Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298(10):1171–1179. doi:10.1001/jama.298.10.1171.
17.Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. doi:10.1093/eurheartj/ehac237.
18.Barst RJ, Ivy D, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324–334. doi:10.1161/CIRCULATIONAHA.110.016667.
19.Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914–1923. doi:10.1161/CIRCULATIONAHA.113.005698.
20.Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med. 2011;37(3):502–509. doi:10.1007/s00134-010-2065-4.
21.Schulze-Neick I, Hartenstein P, Li J, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation. 2003;108(Suppl 1):II167–II173. doi:10.1161/01.CIR.0000087384.76615.60.
22.Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54. doi:10.1161/CIRCULATIONAHA.106.630715.
23.Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107(7):996–1002. doi:10.1161/01.CIR.0000051365.81920.28.
24.Hoffman TM, Wernovsky G, Atz AM, et al. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Am Heart J. 2002;143(1):15–21. doi:10.1067/mhj.2002.120305.
25.Gillies M, Lokuge K, Lally P, et al. Inotropes for the prevention of low cardiac output syndrome and mortality for paediatric patients undergoing surgery for congenital heart disease: a network meta-analysis. Cochrane Database Syst Rev. 2024;(11):CD013707. doi:10.1002/14651858.CD013707.pub2.
26.Ricci Z, Garisto C, Favia I, et al. Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial. Intensive Care Med. 2012;38(7):1198–1204.
27.Wang X, et al. Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial. Crit Care. 2019;23:329. doi:10.1186/s13054-019-2704-2.
28.Lechner E, et al. Prevention of low cardiac output syndrome after pediatric cardiac surgery: a double-blind randomized clinical pilot study comparing dobutamine and milrinone. Pediatr Crit Care Med. 2018;19(7):643–651. doi:10.1097/PCC.0000000000001533.
29.Diao J, Alhabib KF, et al. Heart failure in children and adolescents: an update on diagnostic approaches and management. Front Pediatr. 2024;12:1364359. doi:10.3389/fped.2024.1364359.